Clinical trials: Blindness
Autosomal Dominant Retinitis Pigmentosa, Eye Diseases
A Study to Evaluate the Safety and Tolerability of QR-1123 in Subjects With Autosomal Dominant Retinitis Pigmentosa Due to the P23H Mutation in the RHO Gene
This study evaluates the safety, tolerability and efficacy of QR-1123 injection in the eye (intravitreal; IVT) injections (one eye/unilateral) in subjects receiving a single dose or repeat doses.
- Conditions
- Autosomal Dominant Retinitis Pigmentosa, Eye Diseases, Eye Diseases, Hereditary, Retinal Dystrophies
- Trial name
- AURORA (NCT04123626)
- Testing
- QR-1123
- Where
- 5 sites in United States
- Volunteers
- 11 people
- Sponsor
- ProQR Therapeutics
Retinitis Pigmentosa, Usher Syndromes
Prospective Open Clinical and Genetic Study of Patients With Retinitis Pigmentosa
This study is aimed to characterize Russian population of Retinitis Pigmentosa
- Trial name
- RU-RP (NCT03901391)
- Testing
- Whole Exome Sequencing
- Where
- 2 sites in Russia
- Volunteers
- 130 people
- Sponsor
- Sensor Technology for Deafblind
Corneal Blindness
A Clinical Study to Evaluate the KeraKlear Keratoprosthesis in Patients With Corneal Opacity
To evaluate the safety and probable benefit of the KeraKlear Non-Penetrating Keratoprosthesis when implanted in an eye with corneal opacity that is at high risk of complications with PK.
- Trial name
- NCT03126903
- Testing
- KeraKlear Non-Penetrating Keratoprosthesis
- Where
- 4 sites in United States
- Volunteers
- 11 people
- Sponsor
- KeraMed, Inc.
Retinitis Pigmentosa, Usher Syndrome Type 2
Study to Evaluate Safety and Tolerability of QR-421a in Subjects With RP Due to Mutations in Exon 13 of the USH2A Gene
The purpose of this study is to evaluate the safety and tolerability of QR-421a administered via intravitreal injection (IVT) in subjects with Retinitis Pigmentosa (RP) due to mutations in exon 13 of the USH2A gene.
- Conditions
- Retinitis Pigmentosa, Usher Syndrome Type 2, Deaf Blind, Retinal Disease
- Trial name
- Stellar (NCT03780257)
- Testing
- QR-421a
- Where
- 7 sites in United States, Canada and 1 more
- Volunteers
- 20 people
- Sponsor
- ProQR Therapeutics
Non-24-Hour Sleep-Wake Disorder
Tasimelteon for the Treatment of Non-24-hour Sleep-Wake Disorder (N24HSWD) in Blind Individuals With no Light Perception
The purpose of this study is to evaluate the safety of tasimelteon in male and female patients who suffer from Non-24-Hour Sleep-Wake Disorder.
- Trial name
- NCT01429116
- Testing
- tasimelteon
- Where
- 22 sites in United States
- Volunteers
- 200 people
- Sponsor
- Vanda Pharmaceuticals
Glaucoma, Diabetic Retinopathy (DR)
"My Eyes, My Light": Amar Chokh, Amar Alo
Eye disease affects 2.2 billion people globally, which in turn adversely affects schooling, economic productivity, and participation in social life.
- Conditions
- Glaucoma, Diabetic Retinopathy (DR), Hypertensive Retinopathy, Cataract
- Trial name
- ACA2 (NCT07135570)
- Testing
- Multimodal Screening for Eye Disease, cataract surgery
- Where
- Bangladesh
- Volunteers
- 20,000 people, healthy volunteers welcome
- Sponsor
- Data Yakka, Inc.
Retinal Disease, Age-Related Macular Degeneration
Stem Cell Ophthalmology Treatment Study II
This study will evaluate the use of autologous bone marrow derived stem cells (BMSC) for the treatment of retinal and optic nerve damage or disease.
- Conditions
- Retinal Disease, Age-Related Macular Degeneration, Retinitis Pigmentosa, Stargardt Disease
- Trial name
- SCOTS2 (NCT03011541)
- Testing
- Arm 1
- Where
- 4 sites in United States, Austria and 1 more
- Volunteers
- 500 people
- Sponsor
- MD Stem Cells
Visual Fields Hemianopsia, Hemianopsia, Homonymous
Visual Perceptual Learning Based Digital Therapeutics for Visual Field Defect After Stroke
This study evaluates the efficacy of visual perceptual learning for the treatment of visual field defect caused by brain disease. Half of participants will receive visual perceptual training using the VIVID Brain.
- Trial name
- NCT05525949
- Testing
- VIVID Brain, No-treatment Control
- Where
- 12 sites in South Korea
- Volunteers
- 93 people
- Sponsor
- Nunaps Inc
Chronic Venous Insufficiency, CVI
Clinical Study to Assess the Safety and Efficacy of Mechanochemical Ablation With Flebogrif in Patients With Great Saphenous Vein Insufficiency
The objective of the study is to collect clinical data of patients in whom Flebogrif® will have been used for mechanochemical ablation of incompetent veins in the follow-up period, as related to the safety, clinical…
- Trial name
- POLFLEB (NCT04558957)
- Testing
- FLEBOGRIF
- Where
- 4 sites in Poland
- Volunteers
- 200 people
- Sponsor
- Balton Sp.zo.o.
Retinitis Pigmentosa (RP)
Retrospective Natural History Study of Retinitis Pigmentosa
This is natural history study of rods and cones degenerations in patients with Retinitis Pigmentosa (RP) caused by pathogenic mutations in RHO, PDE6A or PDE6B gene mutations.
- Trial name
- PHENOROD1 (NCT03975543)
- Where
- France
- Volunteers
- 113 people
- Sponsor
- SparingVision
Usher Syndrome, Type 1B
Study of Subretinally Injected AAVB-081 in Patients With Usher Syndrome Type IB (USH1B) Retinitis Pigmentosa
The purpose of the 081-101 study is to evaluate the safety and tolerability of a single subretinal injection of AAVB-081 in USH1B patients with retinitis pigmentosa due to a mutation in the MYO7A gene.
- Trial name
- NCT06591793
- Testing
- AAVB-081
- Where
- 3 sites in Italy, United Kingdom
- Volunteers
- 15 people
- Sponsor
- AAVantgarde Bio Srl
Chronic Venous Insufficiency, CVI, Venous Malformations
Safety of the Sonablate HIFU System for the Ablation of Incompetent Veins of the Periphery
The goal of this clinical trial is to learn if the Sonablate High Intensity Focused Ultrasound device can be safely used to treat patients with Chronic Venous Incompetence (CVI) including those with venous malformations of the…
- Conditions
- Chronic Venous Insufficiency, CVI, Venous Malformations, Venous Leg Ulcers, Klippel-Trenaunay Syndrome
- Trial name
- HIFIVE (NCT06642051)
- Testing
- High Intensity focused ultrasound
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Sonablate
Soil-transmitted Helminth Infection, Onchocerciasis (River Blindness)
A Study to Learn About How Much Emodepside Gets Absorbed in the Blood and How Food Affects Its Absorption When Given as a New Type of Tablet to Healthy Participants
Onchocerciasis or river blindness is an infectious disease caused by a parasitic worm. It spreads through the bite of an infected blackfly.
- Trial name
- NCT06412926
- Testing
- BAY 44-4400
- Where
- Germany
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Bayer
Retinitis Pigmentosa, Usher Syndrome Type 2
Study to Evaluate the Efficacy Safety and Tolerability of Ultevursen in Subjects With RP Due to Mutations in Exon 13 of the USH2A Gene (Sirius)
The purpose of this study is to evaluate the efficacy safety and tolerability of ultevursen administered via intravitreal injection (IVT) in subjects with Retinitis Pigmentosa (RP) due to mutations in exon 13 of the USH2A gene.
- Conditions
- Retinitis Pigmentosa, Usher Syndrome Type 2, Deaf Blind, Retinal Disease
- Trial name
- NCT05158296
- Testing
- Ultevursen
- Where
- 15 sites in United States, Germany and 2 more
- Volunteers
- 7 people
- Sponsor
- Laboratoires Thea
Leber Congenital Amaurosis 10, Inherited Retinal Dystrophies
Single Ascending Dose Study in Participants With LCA10
The purpose of this study is to evaluate the safety, tolerability and efficacy of a single escalating doses of EDIT-101 administered via subretinal injection in participants with LCA10 caused by a homozygous or compound…
- Conditions
- Leber Congenital Amaurosis 10, Inherited Retinal Dystrophies, Eye Diseases, Hereditary, Retinal Disease
- Trial name
- NCT03872479
- Testing
- EDIT-101
- Where
- 5 sites in United States
- Volunteers
- 34 people
- Sponsor
- Editas Medicine, Inc.
Neovascular Age-Related Macular Degeneration (nAMD), Wet AMD
Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-Related Macular Degeneration
This is a multi-center, randomized, double-masked, active-comparator-controlled, Phase 3 study in a broad participant population (treatment-naïve and treatment-experienced) with neovascular (wet) age-related macular degeneration…
- Trial name
- ARTEMIS (NCT06856577)
- Testing
- Ixo-vec, Aflibercept
- Where
- 75 sites in United States
- Volunteers
- 311 people
- Sponsor
- Adverum Biotechnologies, Inc.
Carotid Stenosis, Atherosclerosis
Revacept in Symptomatic Carotid Stenosis
Patients suffering from symptomatic carotid artery stenosis, transient ischemic attacks (TIAs), amaurosis fugax or stroke receive either Revacept (single dose) plus antiplatelet monotherapy or monotherapy alone.
- Conditions
- Carotid Stenosis, Atherosclerosis, Stroke, Transient-ischaemic Attack
- Trial name
- RevaceptCS02 (NCT01645306)
- Testing
- Revacept
- Where
- 12 sites in Germany, United Kingdom
- Volunteers
- 158 people
- Sponsor
- AdvanceCor GmbH
Wet Age-related Macular Degeneration, Neovascular Age-related Macular Degeneration
Long-term Study of ADVM-022 in Neovascular (Wet) AMD [OPTIC-EXT]
ADVM-022-07 is an observational long-term extension (OPTIC-EXT) study assessing safety and efficacy of ADVM-022 gene therapy product, in participants with neovascular, or exudative (wet), age-related macular degeneration (nAMD).
- Trial name
- NCT04645212
- Testing
- ADVM-022
- Where
- 9 sites in United States
- Volunteers
- 23 people
- Sponsor
- Adverum Biotechnologies, Inc.
Lower Extremity Edema, Lower Extremity Edema Chronic
Pedal Pump Clinical Trial on Edema V2
Previous research on the osteopathic manual technique entitled "Pedal Pump" has shown health benefits, specifically increasing lymphatic flow, decreasing lower extremity edema, and decreasing serum lactic acid after maximal…
- Conditions
- Lower Extremity Edema, Lower Extremity Edema Chronic, CHF - Congestive Heart Failure, CHF Exacerbation
- Trial name
- NCT07809516
- Testing
- Pedal Pump
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Hillcrest
Viral Keratitis, Blindness Eye
Safety and Efficacy of CRISPR/Cas9 mRNA Instantaneous Gene Editing Therapy to Treat Refractory Viral Keratitis
The purpose of this study is to evaluate the safety, tolerability and efficacy of a single escalating doses of BD111 CRISPR/Cas9 mRNA Instantaneous Gene Editing Therapy administered via corneal injection in participants with…
- Conditions
- Viral Keratitis, Blindness Eye, Herpes Simplex Virus Infection, Cornea
- Trial name
- NCT04560790
- Testing
- BD111 Adult single group Dose
- Where
- China
- Volunteers
- 3 people
- Sponsor
- Shanghai BDgene Co., Ltd.